内幕人士在Ionis股票中出售了8 800万美元,收入丰厚,股票不断上涨,1月16日。 Insiders sold $8.8M in Ionis shares Jan. 16 amid strong earnings and rising stock.

Ionis Pharmaceuticals（IONS）高管Patrick O'Neil于1月16日以75.84美元卖出9,191股，持股减少12.2%，至66,171股。 Ionis Pharmaceuticals (IONS) executive Patrick O’Neil sold 9,191 shares on January 16 at $75.84, reducing his stake by 12.2% to 66,171 shares. 包括Brett Monia首席执行官在内的多位执行官 在那一天,一个范围更广的内幕出售 共约880万美元 A broader insider sell-off that day totaled about $8.8 million across multiple executives, including CEO Brett Monia. 这股股票在1月21日上升至77.53美元,数量很大,此前,Q3收入报告强劲,比估计数略高,收入增长17.2%。 The stock rose to $77.53 on January 21, with high volume, following a strong Q3 earnings report that beat estimates and showed 17.2% revenue growth. 分析师保持“中度买入”评级, 引用2026年预计推出的SHTG的olezarsen作为关键增长驱动器, Analysts maintain a "moderate buy" rating, citing the 2026 expected launch of olezarsen for SHTG as a key growth driver, despite concerns over the large insider sales.